Literature DB >> 6362357

The forty-year-old mutation theory of Luria and Delbrück and its pertinence to cancer chemotherapy.

H E Skipper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6362357     DOI： 10.1016/s0065-230x(08)60683-1

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN： 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  10 in total

Review 1.  Evolution of acquired resistance to anti-cancer therapy.

Authors:  Jasmine Foo; Franziska Michor
Journal:  J Theor Biol       Date:  2014-03-25       Impact factor: 2.691

Review 2.  Targeting cancer-specific mutations by T cell receptor gene therapy.

Authors:  Thomas Blankenstein; Matthias Leisegang; Wolfgang Uckert; Hans Schreiber
Journal:  Curr Opin Immunol       Date:  2015-02-27       Impact factor: 7.486

3.  On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future).

Authors:  H E Skipper
Journal:  Bull Math Biol       Date:  1986       Impact factor: 1.758

Review 4.  What does physics have to do with cancer?

Authors:  Franziska Michor; Jan Liphardt; Mauro Ferrari; Jonathan Widom
Journal:  Nat Rev Cancer       Date:  2011-08-18       Impact factor: 60.716

Review 5.  Quantitative genetic analysis of tumor progression.

Authors:  V Ling; A F Chambers; J F Harris; R P Hill
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

6.  Tumor cell heterogeneity: divided-colony assay for measuring drug response.

Authors:  T Kuczek; D E Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

7.  Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.

Authors:  D L Hines
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells.

Authors:  Shannon M Mumenthaler; Jasmine Foo; Nathan C Choi; Nicholas Heise; Kevin Leder; David B Agus; William Pao; Franziska Michor; Parag Mallick
Journal:  Cancer Inform       Date:  2015-07-15

9.  Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools.

Authors:  Muthu Dhandapani; Aaron Goldman
Journal:  J Mol Biomark Diagn       Date:  2017-06-30

10.  How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient.

Authors:  Elsa Hansen; Robert J Woods; Andrew F Read
Journal:  PLoS Biol       Date:  2017-02-09       Impact factor: 8.029
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.